11:06 AM EDT, 03/12/2025 (MT Newswires) -- Diagnos ( DGNOF ) on Wednesday said it is filing for Saudi Food and Drug Administration authorization for its CARA System, a machine-learning-enabled medical device. Diagnos ( DGNOF ) is working with Kanhoor Medical, its authorized representative for the Saudi Arabia market.

The eye-health technologies company said the CARA system assists frontline healthcare professionals in processing, analyzing and annotating images for the early detection of diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy.

Using artificial intelligence, Diagnos ( DGNOF ) aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes.

"As per the latest IDF (International Diabetic Federation), the prevalence of diabetes in adults was at 17,7% in Saudi Arabia, or more than 4 million patients at risk of some level of vision loss. Our solution can help triage this population efficiently to prevent permanent damage on vision caused by the complication of diabetes," chief executive Andre Larente said.

The company's shares were last seen up $0.01 to $0.32 on the TSX Venture Exchange.

Price: 0.32, Change: +0.01, Percent Change: +3.23